GPX4 and colorectal cancer: In HT-29 and HCT-116 human colorectal cancer (CRC) cells treated with ferroptosis inducers erastin (SLC7A11 inhibitor) and RSL3 (GPX4 inhibitor), the silencing of miR-545 could increase the levels of intracellular ferroptosis biomarkers malondialdehyde (MDA), reactive oxygen species (ROS) and Fe2+ and reduce the viability of the cells, while the overexpression of miR-545 was the opposite.